COMMENTARY

Data Corroborate Harshness of Z2 Rule, Only Handful to Escape 2nd Consecutive Application

March 31, 2016
As the Ministry of Health, Labor and Welfare (MHLW) has released a list of new reimbursement prices for listed drugs, which will be effective April 1, we’ve seen a raft of long-listed products slapped with the so-called Z2 price cut…

To read the full story

COMMENTARY

The Ministry of Health, Labor and Welfare (MHLW) on November 22 proposed two rules designed to address windfall price rises enjoyed by cheaply sold generics - a problematic fallout from the current three price-band grouping rule.The rules formed part of…

A raft of new medicines will be added to Japan’s NHI price list on November 19, with a key reimbursement…

Combined sales of eight major Japanese drug makers grew nearly 26% year on year in April-September, pushed up by the acquisition of Shire by Takeda Pharmaceutical. Even excluding the industry leader, though, seven firms still collectively eked out a slight…

By Reiji Anasako

Indian generic maker Lupin is casting off Kyowa Pharmaceutical Industry, which it acquired in 2007. Forking over 57.4 billion yen…

By Yoshinori Sagehashi

As Japan gears up for its next drug pricing reform in April 2020, Shoji Kono, director of the National Federation…

By Reiji Anasako

Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…

By Reiji Anasako

Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…

By Yoshinori Sagehashi

Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

By Philip Carrigan

While the digital transformation may only be in its infancy in the pharmaceutical industry, the winds of change are here. It’s only a matter of time until customers and patients demand a higher level of service, experience, and connectivity from…